Endpoints Webinars

Life sciences marketers work with long sales cycles and products that require market education — which make webinars one of the most essential tools in the biopharma demand generation toolbox. 

Endpoints webinars are a turn-key solution — let us handle the audience generation, content, marketing, and tech.

Upcoming Webinars

AI, Digital Twins, and the Future of Clinical Research

past Webinars

When cell and gene therapies surge to market, how resilient will your cell sourcing infrastructure be?

The Australian Early Phase Biosimilars Clinical Trial Landscape - How Agilex Biolabs and Nucleus Network Work Together

The FDA and Covid-19: New rules for the R&D road

Novel oncology trial designs with a personalized ctDNA assay

Derisking orphan drug programs in 2020 and beyond

A Clinical Investigator’s Perspective: Novel Oncology Therapy During & Beyond the COVID Pandemic

Home Nursing Support for Clinical Trials

Running First-in-human and Vaccines Studies in Australia

How Easy is it to Move your Clinical Trials to Australia?

Utilizing the immunoSEQ Assay in Clinical Trials

The Covid-19 challenge: Keeping the supply chain intact

Dealmaking in a time of coronavirus

Endpoints Editor John Carroll's Covid - 19 webinar series

Advancing Oncology Clinical Trials in Asia-Pacific

Asia-Pacific – a Global hub for Hepatology Clinical Trials

Rapid Deployment of Remote Trials During Containment

RWD for R&D: Examples from Immunology, Rheumatology and Other Chronic Diseases

Designing a turnkey orphan drug program

The do’s and don’ts of managing a pivotal gene therapy trial

You've got that coveted accelerated regulatory pathway. Now what?

Developing better assays for biopharma with a CRO partner

Are you really ready for your end of phase 2 meeting?

How to run a Digital Trial and reduce time in development by 50%

Improving Clinical Trial Quality with Best Practices for E-Clinical Technology

Developing a digital therapeutics trial

The Experts: Real World Endpoints

Designing Next-Gen Oncology Trials

ctDNA as a biomarker for monitoring treatment response and molecular recurrence in early-stage and metastatic cancers

How to get the most out of your Phase I biologic study

The Alzheimer's Trials of the Future